SG Americas Securities LLC Has $32.35 Million Holdings in Biogen Inc. $BIIB

SG Americas Securities LLC increased its holdings in Biogen Inc. (NASDAQ:BIIB) by 1,793.8% during the 4th quarter, HoldingsChannel.com reports. The firm owned 183,829 shares of the biotechnology company’s stock after purchasing an additional 174,122 shares during the period. SG Americas Securities LLC’s holdings in Biogen were worth $32,352,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Empowered Funds LLC raised its position in Biogen by 64.9% during the 1st quarter. Empowered Funds LLC now owns 7,054 shares of the biotechnology company’s stock worth $965,000 after purchasing an additional 2,777 shares during the last quarter. Focus Partners Wealth increased its stake in shares of Biogen by 172.2% in the first quarter. Focus Partners Wealth now owns 10,173 shares of the biotechnology company’s stock valued at $1,392,000 after buying an additional 6,436 shares during the period. Sivia Capital Partners LLC bought a new position in shares of Biogen during the second quarter worth about $216,000. Cetera Investment Advisers raised its position in shares of Biogen by 2.2% during the second quarter. Cetera Investment Advisers now owns 12,888 shares of the biotechnology company’s stock worth $1,619,000 after acquiring an additional 280 shares during the last quarter. Finally, MAI Capital Management lifted its stake in shares of Biogen by 33.3% in the second quarter. MAI Capital Management now owns 776 shares of the biotechnology company’s stock worth $97,000 after acquiring an additional 194 shares during the period. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

BIIB has been the topic of several analyst reports. Sanford C. Bernstein reiterated a “market perform” rating on shares of Biogen in a report on Monday, February 9th. TD Cowen boosted their price target on shares of Biogen from $175.00 to $215.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. Wedbush upped their price objective on shares of Biogen from $178.00 to $187.00 and gave the company a “neutral” rating in a research note on Monday, February 9th. Canaccord Genuity Group increased their price objective on shares of Biogen from $220.00 to $230.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. Finally, HSBC lifted their target price on shares of Biogen from $143.00 to $150.00 and gave the stock a “reduce” rating in a research note on Tuesday, March 17th. Twelve investment analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $205.31.

Biogen Trading Up 2.8%

Shares of BIIB stock opened at $189.18 on Thursday. Biogen Inc. has a fifty-two week low of $110.04 and a fifty-two week high of $202.41. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.03 and a current ratio of 2.68. The stock has a 50 day simple moving average of $184.53 and a two-hundred day simple moving average of $169.61. The company has a market cap of $27.76 billion, a P/E ratio of 21.47, a PEG ratio of 1.46 and a beta of 0.15.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.61 by $0.38. The firm had revenue of $2.28 billion for the quarter, compared to analysts’ expectations of $2.21 billion. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The company’s revenue for the quarter was down 7.2% compared to the same quarter last year. During the same period in the prior year, the business earned $3.44 EPS. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Research analysts forecast that Biogen Inc. will post 15.83 earnings per share for the current year.

Insider Transactions at Biogen

In related news, insider Priya Singhal sold 2,660 shares of the stock in a transaction on Monday, February 9th. The shares were sold at an average price of $199.83, for a total transaction of $531,547.80. Following the transaction, the insider directly owned 8,043 shares of the company’s stock, valued at $1,607,232.69. This represents a 24.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.18% of the stock is currently owned by corporate insiders.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.